MCID: INT002
MIFTS: 63

Intermittent Claudication

Categories: Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Intermittent Claudication

MalaCards integrated aliases for Intermittent Claudication:

Name: Intermittent Claudication 38 12 55 44 15 73
Amyotrophic Lateral Sclerosis 73
Charcot's Syndrome 12
Charcot Disease 76

Classifications:



External Ids:

Disease Ontology 12 DOID:3669
ICD10 33 I73.9
MeSH 44 D007383
SNOMED-CT 68 63491006

Summaries for Intermittent Claudication

MalaCards based summary : Intermittent Claudication, also known as amyotrophic lateral sclerosis, is related to critical limb ischemia and peripheral artery disease, and has symptoms including seizures, tremor and polydipsia. An important gene associated with Intermittent Claudication is HTR2A (5-Hydroxytryptamine Receptor 2A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Angiotensin II and Olmesartan have been mentioned in the context of this disorder. Affiliated tissues include Placenta, bone and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 76 Charcot�??Marie�??Tooth disease (CMT) is one of the hereditary motor and sensory neuropathies, a group... more...

Related Diseases for Intermittent Claudication

Diseases related to Intermittent Claudication via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 288)
# Related Disease Score Top Affiliating Genes
1 critical limb ischemia 32.7 IL6 VEGFA
2 peripheral artery disease 32.2 ACE CRP IL6 SELP VEGFA
3 limb ischemia 30.2 ACE ANGPT2 IL6 VEGFA VWF
4 carotid stenosis 30.0 ACE CRP SELP
5 arteriosclerosis 29.9 ACE CRP IL6 SELP SERPINE1
6 aortic aneurysm, familial abdominal, 1 29.9 ACE CRP IL6
7 arteries, anomalies of 29.8 ACE ALB CRP IL6 SELP SERPINC1
8 coronary artery anomaly 29.8 ACE CRP F2 SELP SERPINE1
9 systolic heart failure 29.8 ACE CRP IL6
10 arteriovenous fistula 29.8 APOH IL6
11 diabetes mellitus 29.8 ACE ALB CRP IL6 SERPINE1 VEGFA
12 temporal arteritis 29.7 APOH CRP IL6
13 angina pectoris 29.7 ACE CRP IL6 SERPINC1 VWF
14 polyarteritis nodosa 29.6 APOH CRP IL6
15 thrombophilia 29.3 APOH F2 SERPINC1 SERPINE1 VWF
16 infective endocarditis 29.2 APOH CRP F2 IL6 SERPINE1
17 thrombosis 29.1 APOH F2 SELP SERPINC1 SERPINE1 VWF
18 peripheral vascular disease 28.9 ACE ALB CRP F2 IL6 SELP
19 endocarditis 28.8 ALB APOH CRP F2 IL6 SERPINC1
20 myocardial infarction 28.8 ACE ALB CRP F2 IL6 SELP
21 heart disease 28.5 ACE ALB CRP F2 IL6 SELP
22 vascular disease 28.3 ACE ALB APOH CRP F2 IL6
23 amyotrophic lateral sclerosis 1 11.5
24 juvenile amyotrophic lateral sclerosis 11.4
25 ischemia 10.5
26 spinal stenosis 10.4
27 cystic adventitial disease 10.3
28 carotid artery thrombosis 10.3 SELP SERPINE1
29 infiltrating angiolipoma 10.3 VEGFA VWF
30 hypertensive retinopathy 10.3 ACE VWF
31 burns 10.3 CRP SERPINC1
32 japanese spotted fever 10.3 CRP SERPINC1
33 aspirin allergy 10.2 SERPINC1 SERPINE1
34 argentine hemorrhagic fever 10.2 SERPINC1 SERPINE1
35 sticky platelet syndrome 10.2 SERPINC1 SERPINE1
36 pyuria 10.2 ALB CRP
37 gastrointestinal tuberculosis 10.2 ALB CRP
38 decubitus ulcer 10.2 ALB CRP
39 brachydactyly, type d 10.2 F2 VWF
40 factor viii deficiency 10.2 F2 VWF
41 von willebrand disease, type 1 10.2 F2 VWF
42 acroosteolysis 10.2 ALB VEGFA
43 active peptic ulcer disease 10.2 F2 VWF
44 renal artery obstruction 10.2 ACE SERPINC1
45 severe nonproliferative diabetic retinopathy 10.2 ALB VEGFA
46 coronary restenosis 10.2 ACE SERPINC1
47 ischemic neuropathy 10.2 CRP F2
48 chronic thromboembolic pulmonary hypertension 10.2 CRP F2
49 cryptogenic cirrhosis 10.2 F2 SERPINE1
50 orthostatic proteinuria 10.2 ACE ALB

Comorbidity relations with Intermittent Claudication via Phenotypic Disease Network (PDN):


Acute Cystitis Motor Neuron Disease
Primary Lateral Sclerosis, Adult, 1 Protein-Energy Malnutrition
Respiratory Failure Swallowing Disorders

Graphical network of the top 20 diseases related to Intermittent Claudication:



Diseases related to Intermittent Claudication

Symptoms & Phenotypes for Intermittent Claudication

UMLS symptoms related to Intermittent Claudication:


seizures, tremor, polydipsia, fatigue, edema, back pain, pain, headache, syncope, cyanosis, chronic pain, sciatica, asthenia, chills, renal colic, signs and symptoms, signs and symptoms, digestive, hot flushes, vertigo/dizziness, sleeplessness, eye manifestations, oral manifestations, urological manifestations, hypertriglyceridemic waist, body temperature changes, signs and symptoms, respiratory, skin manifestations, mobility limitation, prodromal symptoms, medically unexplained symptoms

MGI Mouse Phenotypes related to Intermittent Claudication:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.16 ACE ANGPT2 CRP F2 IL6 SELP
2 homeostasis/metabolism MP:0005376 10.15 ACE ALB ANGPT2 APOH CRP F2
3 immune system MP:0005387 10.02 ACE ANGPT2 CRP F2 IL6 SELP
4 hematopoietic system MP:0005397 10.01 ACE F2 IL6 SELP SERPINC1 SERPINE1
5 digestive/alimentary MP:0005381 9.98 ALB ANGPT2 F2 HTR2A IL6 VEGFA
6 mortality/aging MP:0010768 9.9 ACE ALB ANGPT2 APOH F2 IL6
7 liver/biliary system MP:0005370 9.8 ACE ALB IL6 SELP SERPINC1 SERPINE1
8 renal/urinary system MP:0005367 9.5 ACE ALB IL6 SELP SERPINC1 SERPINE1
9 respiratory system MP:0005388 9.1 ANGPT2 F2 IL6 SELP SERPINE1 VEGFA

Drugs & Therapeutics for Intermittent Claudication

Drugs for Intermittent Claudication (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 261)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
2
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
3
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 33069-62-4 36314
4
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
5
Gliclazide Approved Phase 4 21187-98-4 3475
6
Glyburide Approved Phase 4 10238-21-8 3488
7
Pioglitazone Approved, Investigational Phase 4,Phase 2,Phase 3 111025-46-8 4829
8
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
9
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73963-72-1 2754
10
Losartan Approved Phase 4 114798-26-4 3961
11
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
12
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
13
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
14
Pentoxifylline Approved, Investigational Phase 4,Phase 3 6493-05-6 4740
15
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
16
Simvastatin Approved Phase 4,Phase 2,Not Applicable 79902-63-9 54454
17
Alprostadil Approved, Investigational Phase 4,Phase 3,Phase 2 745-65-3 149351 5280723
18
Pregabalin Approved, Illicit, Investigational Phase 4,Not Applicable 148553-50-8 5486971
19
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 113665-84-2, 120202-66-6 60606
20
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
21
Allopurinol Approved Phase 4 315-30-0 2094
22
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable 9005-49-6 772 46507594
23
Ramipril Approved Phase 4 87333-19-5 5362129
24
Menthol Approved Phase 4,Phase 2,Phase 3,Not Applicable 2216-51-5 16666
25
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
26
Promethazine Approved, Investigational Phase 4 60-87-7 4927
27
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
28
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Not Applicable 55142-85-3 5472
29
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Not Applicable 1177-87-3
30
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Not Applicable 50-02-2 5743
31
Amlodipine Approved Phase 4 88150-42-9 2162
32
Nicotinamide Approved, Investigational Phase 4,Phase 3,Not Applicable 98-92-0 936
33
Ezetimibe Approved Phase 4 163222-33-1 150311
34
Thrombin Approved, Investigational Phase 4
35
Verapamil Approved Phase 4,Phase 2 52-53-9 2520
36
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Not Applicable 274693-27-5 9871419
37
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
38 tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
39
Vorapaxar Approved Phase 4 618385-01-6
40
Adenosine Approved, Investigational Phase 4,Phase 2,Not Applicable 58-61-7 60961
41
Acetaminophen Approved Phase 4 103-90-2 1983
42
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
43
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
44
Ranolazine Approved, Investigational Phase 4,Not Applicable 142387-99-3, 95635-55-5 56959
45
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Not Applicable 59-67-6 938
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 59-30-3 6037
47
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
48
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
49
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
50
2,4-thiazolidinedione Investigational Phase 4 2295-31-0

Interventional clinical trials:

(show top 50) (show all 451)
# Name Status NCT ID Phase Drugs
1 Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF) Unknown status NCT02373462 Phase 4 Olmesartan;other anti-hypertensive drug
2 ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion Unknown status NCT00407940 Phase 4
3 Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis Unknown status NCT02033135 Phase 4
4 Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
5 Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness Unknown status NCT00573950 Phase 4 cilostazol;Placebo
6 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
7 Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease Unknown status NCT00144937 Phase 4 Stepwise therapy for dyslipidemia, hypertension and diabetes
8 Self Expanding Nitinol Stent Versus Percutaneous Transluminal Arterial Angioplasty (PTA) With Optional Bailout Stenting in Case of PTA Failure in Patients With Symptomatic Critical Limb Ischemia or Severe Intermittent Claudication (EXPAND) Completed NCT00906022 Phase 4
9 Neurogenic Intermittent Claudication Evaluation Study Completed NCT00905359 Phase 4
10 Evaluation of Cilostazol in Combination With L-Carnitine Completed NCT00822172 Phase 4 cilostazol
11 Intermittent Neurogenic Claudication Treatment With APERIUS® Completed NCT00887744 Phase 4
12 A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis Completed NCT01888536 Phase 4 Limaprost;Pregabalin;Placebo(for Pregabalin);Placebo(for Limaprost)
13 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4 Aspirin
14 Allopurinol as a Possible Oxygen Sparing Agent During Exercise in Peripheral Arterial Disease Completed NCT01147705 Phase 4 Allopurinol;Placebo
15 Study of SilverHawk®/TurboHawk® in Lower Extremity Vessels (DEFINITIVE™ LE) Completed NCT00883246 Phase 4
16 Angioplasty in Peripheral Arterial Disease and Endothelial Function Completed NCT00660634 Phase 4
17 PTA vs. Primary Stenting of SFA Using Self-Expandable Nitinol Stents Completed NCT00715416 Phase 4
18 Choice of Material for Above-Knee Femoro-Popliteal Bypass Prosthetic Graft (PopUp) Completed NCT00300690 Phase 4
19 4-EVER : a Trial Investigating the Safety of 4F Endovascular Treatment of Infra-Inguinal Arterial Stenotic Disease Completed NCT01413139 Phase 4
20 Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants Completed NCT01037530 Phase 4 Ramipril
21 DURABILITY-200: EverFlex 200mm Long Nitinol Stents in TASC C&D Femoropopliteal Lesions Completed NCT00637741 Phase 4
22 Lumbar Stenosis Outcomes Research (LUSTOR) Completed NCT00638443 Phase 4 Pregabalin;Diphenhydramine
23 The Effects of Physical Training, ASA (Aspirin), and Clopidogrel on the Walking Capacity of Patients With Stage II Peripheral Arterial Disease (PAD) Completed NCT00189618 Phase 4 Aspirin;Clopidogrel
24 Efficacy Study of Iliac Stents to Treat TASC A-B-C-D Iliac Artery Lesions Completed NCT00764777 Phase 4
25 The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease Completed NCT00168467 Phase 4 Ramipril
26 Intermittent Mechanical Compression For Peripheral Arterial Disease Completed NCT00855673 Phase 4 Control
27 Arterial Inflow and Muscle Ischemia During Calf Stimulation With the Veinoplus Device Completed NCT01592812 Phase 4
28 Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease Completed NCT01983449 Phase 4 Dexamethasone Sodium Phosphate Injection, USP
29 Peripheral Vascular Disease and Nerve Stimulation Completed NCT01942941 Phase 4
30 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study Completed NCT00228384 Phase 4
31 Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors Completed NCT00407537 Phase 4 Amlodipine besylate/atorvastatin calcium single pill combination
32 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study) Completed NCT00687076 Phase 4 Ezetimibe;Niaspan;Statin therapy;Aspirin;Clopidogrel;Placebo Niaspan;Placebo Ezetimibe
33 Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure Completed NCT02903225 Phase 4
34 Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial) Recruiting NCT02660866 Phase 4 Placebo + background APT + SMT;Vorapaxar 2.08 mg/d + background APT + SMT.
35 Ramipril Treatment of Claudication Recruiting NCT02842424 Phase 4 Ramipril
36 Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging Recruiting NCT02807779 Phase 4 Dexamethasone infusion
37 Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease Not yet recruiting NCT03493412 Phase 4 Sapropterin Dihydrochloride (BH4, tetrahydrobiopterin);Placebo
38 The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication Terminated NCT01799057 Phase 4 Metformin;Placebo
39 Cilostazol After Lower Extremity Arterial Revascularization Trial Terminated NCT02374957 Phase 4 Cilostazol
40 Ticagrelor and Peripheral Arterial Disease Terminated NCT02407314 Phase 4 Aspirin;Aspirin + Ticagrelor
41 Condition of Approval Study Terminated NCT00517751 Phase 4
42 Study on the Treatment of Degenerative Lumbar Spine Stenosis With a Percutaneous Interspinous Implant Terminated NCT01057641 Phase 4
43 Balloon Angioplasty vs. Cutting Balloon Angioplasty of Femoropopliteal Arteries- a Randomized Controlled Trial Terminated NCT00437905 Phase 4
44 Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease Terminated NCT01901224 Phase 4 Metformin 1000 mg;Placebo
45 Vitamin D and Walking Ability in Patients With Peripheral Artery Occlusive Disease Terminated NCT01559974 Phase 4 Placebo;Cholecalciferol
46 Lumbar Stenosis Outcomes Research II Terminated NCT00652093 Phase 4 opana then darvocet then placebo;opana then placebo then darvocet;placebo then opana then darvocet;Placebo then darvocet then opana;Darvocet then opana then placebo;Darvocet then placebo then opana
47 Effects of X-STOP® Versus Laminectomy Study Withdrawn NCT00558129 Phase 4
48 Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients Withdrawn NCT02121288 Phase 4 Ticagrelor;clopidogrel
49 Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease Withdrawn NCT00657514 Phase 4 Ranolazine;Placebo
50 PROVIDENCE-1: Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients Unknown status NCT00251849 Phase 3 Rifalazil

Search NIH Clinical Center for Intermittent Claudication

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Intermittent Claudication cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: intermittent claudication

Genetic Tests for Intermittent Claudication

Anatomical Context for Intermittent Claudication

MalaCards organs/tissues related to Intermittent Claudication:

41
Bone, Brain, Testes, Endothelial, Spinal Cord, Bone Marrow, Skeletal Muscle
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Intermittent Claudication:
# Tissue Anatomical CompartmentCell Relevance
1 Placenta Chorionic Villus Chorionic Mesenchymal Stromal Cells Potential therapeutic candidate

Publications for Intermittent Claudication

Articles related to Intermittent Claudication:

(show top 50) (show all 1930)
# Title Authors Year
1
Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia, and frontotemporal dementia. ( 30348461 )
2019
2
Three-curve rocker-soled shoes and gait adaptations to intermittent claudication pain: A randomised crossover trial. ( 30265963 )
2019
3
Elucidating the End-of-Life Experience of Persons With Amyotrophic Lateral Sclerosis. ( 30422919 )
2019
4
Amyotrophic lateral sclerosis as a synaptopathy. ( 30530995 )
2019
5
Amyotrophic lateral sclerosis: a complex syndrome that needs an integrated research approach. ( 30530996 )
2019
6
Safety of intrathecal injection of Wharton's jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy. ( 30531015 )
2019
7
Misdiagnosis: Hypoglossal palsy mimicking bulbar onset amyotrophic lateral sclerosis. ( 30555942 )
2019
8
Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction. ( 30290270 )
2019
9
Mutation analysis of KIF5A in Chinese amyotrophic lateral sclerosis patients. ( 30301576 )
2019
10
Genetic activation of parkin rescues TAF15-induced neurotoxicity in a Drosophila model of amyotrophic lateral sclerosis. ( 30339961 )
2019
11
UNC13A polymorphism contributes to frontotemporal disease in sporadic amyotrophic lateral sclerosis. ( 30368160 )
2019
12
Defective daily temperature regulation in a mouse model of amyotrophic lateral sclerosis. ( 30031021 )
2019
13
Safety, Feasibility of Intravenous and Intrathecal Injection of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Patients with Amyotrophic Lateral Sclerosis: An Open Label Phase I Clinical Trial. ( 30124008 )
2019
14
Regarding "Exercise training for intermittent claudication". ( 29389435 )
2018
15
Beet the Best? Dietary Inorganic Nitrate to Augment Exercise Training in Lower Extremity Peripheral Artery Disease with Intermittent Claudication. ( 29976553 )
2018
16
Achilles tendon elasticity decreases with intermittent claudication in patients by Acoustic Radiation Force Impulse Imaging (ARFI). ( 29371711 )
2018
17
Comparison of EQ-5D and SF-36 in untreated patients with symptoms of intermittent claudication. ( 29855189 )
2018
18
Primary Stenting of the Superficial Femoral Artery in Patients with Intermittent Claudication Has Durable Effects on Health-Related Quality of Life at 24 Months: Results of a Randomized Controlled Trial. ( 29520431 )
2018
19
WITHDRAWN: Angioplasty (versus non surgical management) for intermittent claudication. ( 29521415 )
2018
20
Combination of endovascular revascularization and supervised exercise therapy for intermittent claudication: a systematic review and meta-analysis. ( 29327569 )
2018
21
Translation and Validation of the Brazilian-Portuguese Short Version of Vascular Quality of Life Questionnaire in Peripheral Artery Disease Patients with Intermittent Claudication Symptoms. ( 29772330 )
2018
22
Extracorporeal shockwave therapy for intermittent claudication: Medium-term outcomes from a double-blind randomised placebo-controlled pilot trial. ( 29722640 )
2018
23
YORwalK: Desiging a Smartphone Exercise Application for People with Intermittent Claudication. ( 29677973 )
2018
24
Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. ( 29627967 )
2018
25
Stenosis of the iliac artery after kidney transplantation as a cause of refractory hypertension and intermittent claudication. ( 29731012 )
2018
26
Exploring physical activity behaviour - needs for and interest in a technology-delivered, home-based exercise programme among patients with intermittent claudication. ( 29144207 )
2018
27
Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study. ( 29798770 )
2018
28
Preferred exercise modalities in patients with intermittent claudication. ( 29747787 )
2018
29
Intermittent Claudication due to Cystic Adventitial Disease of the Popliteal Artery: Importance of Multiple Imaging Modalities. ( 29625518 )
2018
30
Joint moment strategies during stair descent in patients with peripheral arterial disease and intermittent claudication. ( 29625411 )
2018
31
Risk of major amputation in patients with intermittent claudication undergoing early revascularization. ( 29566427 )
2018
32
Endovascular revascularisation versus conservative management for intermittent claudication. ( 29518253 )
2018
33
Use of Telehealth as a New Model for Following Intermittent Claudication and Promoting Patient Expertise. ( 29323628 )
2018
34
Cardiovascular and all-cause mortality in patients with intermittent claudication and critical limb ischaemia. ( 29116654 )
2018
35
Systematic review and meta-analysis of high-pressure intermittent limb compression for the treatment of intermittent claudication. ( 29389425 )
2018
36
Reversal of Lower-Extremity Intermittent Claudication and Rest Pain by Hydration. ( 29481920 )
2018
37
Home-based exercise for elderly patients with intermittent claudication limited by osteoarticular disorders - feasibility and effectiveness of a low-intensity programme. ( 29463192 )
2018
38
SIRT1 deacetylase in aging-induced neuromuscular degeneration and amyotrophic lateral sclerosis. ( 30295421 )
2018
39
Alexithymia in Amyotrophic Lateral Sclerosis and Its Neural Correlates. ( 30087649 )
2018
40
The multidimensional nature of dyspnoea in amyotrophic lateral sclerosis patients with chronic respiratory failure: Air hunger, anxiety and fear. ( 30509697 )
2018
41
Is psychological stress a predisposing factor for amyotrophic lateral sclerosis (ALS)? An online international case-control study of premorbid life events, occupational stress, resilience and anxiety. ( 30240431 )
2018
42
A case of Progressive Non-Fluent Aphasia as onset of Amyotrophic Lateral Sclerosis with FrontoTemporal Dementia. ( 30146930 )
2018
43
Three new case reports of Arteriovenous malformation-related Amyotrophic Lateral Sclerosis. ( 30114551 )
2018
44
Moral judgment in patients with behavioral variant of frontotemporal dementia and amyotrophic lateral sclerosis: no impairment of the moral position, but rather its execution. ( 30513214 )
2018
45
Disability in amyotrophic lateral sclerosis compared with traumatic brain injury using the World Health Organization Disability Assessment Schedule 2.0 and the International Classification of Functioning minimal generic set. ( 30095553 )
2018
46
Texture Analysis to Detect Cerebral Degeneration in Amyotrophic Lateral Sclerosis. ( 30234470 )
2018
47
Recurrent complex regional pain syndrome type I in a patient with amyotrophic lateral sclerosis: a case report. ( 29524044 )
2018
48
Non-coding RNA in C9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia: A perfect storm of dysfunction. ( 30533567 )
2018
49
Rare TBK1 variants in patients with frontotemporal dementia and amyotrophic lateral sclerosis in a Chinese cohort. ( 30534373 )
2018
50
Angiopoietin-1 and ανβ3 integrin peptide promote the therapeutic effects of L-serine in an amyotrophic lateral sclerosis/Parkinsonism dementia complex model. ( 30476904 )
2018

Variations for Intermittent Claudication

Expression for Intermittent Claudication

Search GEO for disease gene expression data for Intermittent Claudication.

Pathways for Intermittent Claudication

Pathways related to Intermittent Claudication according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.35 ALB ANGPT2 APOH F2 SELP SERPINC1
2 11.87 HTR2A IL6 VEGFA
3
Show member pathways
11.87 F2 SERPINC1 SERPINE1 VWF
4 11.73 ALB IL6 VEGFA
5 11.7 F2 SERPINC1 SERPINE1 VWF
6
Show member pathways
11.69 ALB CRP F2 IL6 SERPINE1
7 11.58 IL6 SERPINE1 VEGFA
8 11.46 ANGPT2 IL6 SERPINE1 VEGFA
9 11.07 ANGPT2 SERPINE1 VEGFA
10 10.89 ANGPT2 SERPINE1
11 10.74 CRP IL6

GO Terms for Intermittent Claudication

Cellular components related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.91 ACE ALB APOH F2 SERPINC1 SERPINE1
2 extracellular region GO:0005576 9.7 ACE ALB ANGPT2 APOH CRP F2
3 endoplasmic reticulum lumen GO:0005788 9.62 ALB F2 IL6 SERPINC1
4 blood microparticle GO:0072562 9.58 ALB F2 SERPINC1
5 collagen-containing extracellular matrix GO:0062023 9.56 APOH SERPINC1 SERPINE1 VWF
6 platelet alpha granule lumen GO:0031093 9.46 ALB SERPINE1 VEGFA VWF
7 extracellular space GO:0005615 9.36 ACE ALB ANGPT2 APOH CRP F2

Biological processes related to Intermittent Claudication according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.88 F2 IL6 SERPINE1 VEGFA
2 cellular protein metabolic process GO:0044267 9.76 ALB F2 IL6 SERPINC1
3 positive regulation of angiogenesis GO:0045766 9.74 ANGPT2 SERPINE1 VEGFA
4 platelet activation GO:0030168 9.72 F2 IL6 VWF
5 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.7 HTR2A IL6 VEGFA
6 defense response to Gram-negative bacterium GO:0050829 9.69 IL6 SELP SERPINE1
7 hemostasis GO:0007599 9.61 F2 SERPINC1 VWF
8 fibrinolysis GO:0042730 9.58 F2 SERPINE1
9 negative regulation of blood coagulation GO:0030195 9.56 APOH SERPINE1
10 positive regulation of leukocyte migration GO:0002687 9.54 SELP VEGFA
11 acute-phase response GO:0006953 9.54 CRP F2 IL6
12 blood coagulation, intrinsic pathway GO:0007597 9.5 APOH F2 VWF
13 negative regulation of lipid storage GO:0010888 9.49 CRP IL6
14 neutrophil mediated immunity GO:0002446 9.48 ACE IL6
15 positive regulation of blood coagulation GO:0030194 9.43 APOH F2 SERPINE1
16 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.4 ACE VEGFA
17 regulation of blood coagulation GO:0030193 9.33 APOH F2 SERPINC1
18 negative regulation of fibrinolysis GO:0051918 9.13 APOH F2 SERPINE1
19 platelet degranulation GO:0002576 9.1 ALB APOH SELP SERPINE1 VEGFA VWF

Molecular functions related to Intermittent Claudication according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 ALB APOH CRP SERPINC1 VEGFA VWF
2 growth factor activity GO:0008083 9.5 F2 IL6 VEGFA
3 protease binding GO:0002020 9.43 SERPINC1 SERPINE1 VWF
4 drug binding GO:0008144 9.13 ACE ALB HTR2A
5 heparin binding GO:0008201 9.02 APOH F2 SELP SERPINC1 VEGFA

Sources for Intermittent Claudication

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....